

Cardiovascular Changes in Neonates with Unconjugated Hyperbilirubinemia

Thesis

Submitted in Partial Fulfillment of
M.D. Degree in Pediatrics

Presented by:

Angie Mohamed Samir Tosson
M.Sc. Pediatrics - Cairo University

Supervised by:

Dr. Amira AbdelFatah Edris
Professor of Pediatrics
Faculty of Medicine-Cairo University

Dr. Hanna Mohamed AboulGhar
Professor of Pediatrics
Faculty of Medicine-Cairo University

Dr. Rasha Ibrahim Ammar
Assistant Professor of Pediatrics
Faculty of Medicine-Cairo University

Dr. Wael Ahmed Attia
Lecturer of Pediatrics
Faculty of Medicine-Cairo University

Faculty of Medicine
Cairo University
2011

Acknowledgment

A word of thanks to **ALLAH**, the source of all knowledge, by whose abundant grace, this work has come to life.

I wish to express my gratitude to those who generously helped me in carrying out this work with their knowledge, valuable advices and kind encouragements.

I would like to express my sincere thanks, deep gratitude, and extreme appreciation to **Prof. Dr. Amira AbdelFatah Edris**, Professor of Pediatrics, Faculty of Medicine, Cairo University, for her remarkable help, indispensable advice and encouragement throughout this work.

I wish to express my deep everlasting gratitude to **Prof. Dr. Hanna Mohamed AboulGhar**, Professor of Pediatrics, Faculty of Medicine, Cairo University, for her kind supervision, valuable advice and remarks.

I am very grateful to **Dr. Rasha Ibrahim Ammar**, Assistant Professor of Pediatrics, Faculty of Medicine, Cairo University, for her kind supervision, valuable support and comments throughout this work.

I am very grateful to **Dr. Wael Ahmed Attia**, Lecturer of Pediatrics, Faculty of Medicine, Cairo University, not only for his kind assistance and support, but also for his fruitful advice and constant valuable guidance.

I would like to thank also all the staff members of the Neonatology department, Cairo University for their help, support and cooperation.

Last but not least, I am deeply thankful and always indebted to my parents and my brother, who were always there for me, supporting, encouraging and loving me.

Table of Contents

	Page
List of Tables	i
List of Figures	iii
List of Abbreviations	v
Abstract	vii
Introduction	1
Aim of Work	3
Review of Literature	4
Chapter 1 : Neonatal Hyperbilirubinemia	4
Chapter 2: Neonatal Echocardiography	51
Chapter 3: Mechanism of Bilirubin Toxicity	80
Patients and Methods	86
Results	88
Discussion	119
Summary and Recommendations	134
References	137
Arabic Summary	153

List of Tables

	Page
Table 1 : Risk Factors for Hyperbilirubinemia in Newborns	9
Table 2 : Classification of Neonatal Hyperbilirubinemia Based on Mechanism of Accumulation	11
Table 3 : Key Recommendations for Practice of a case with hyperbilirubinemia	21
Table 4 : Laboratory Evaluation of Neonatal Hyperbilirubinemia	23
Table 5 : Timing of Follow-up	48
Table 6 : Summary of Some NICU Data (Gestational Age, Admission Data, Duration of Stay in NICU)	90
Table 7 : Summary of Family History	90
Table 8 : Summary of Pregnancy and Delivery Data	91
Table 9 : Summary of Serum Bilirubin and Onset of Jaundice	92
Table 10 : Summary and Statistical Analysis of Clinical and laboratory Data among the Three Different Groups of Unconjugated Hyperbilirubinemia	95
Table 11 : Summary and Statistical Analysis of Echogardiographic Parameters among the Three Different Groups of Unconjugated Hyperbilirubinemia	99
Table 12 : Summary and Statistical Analysis of Echogardiographic Parameters among Cardiac Neonates (Group A) and Non-cardiac Neonates (Group B)	102
Table 13 : Summary of Some NICU Data (Gestational Age, Admission Data, Duration of Stay in NICU)	107

List of Tables continue....

	Page
Table 14 : Summary of Family History in Group A and B	108
Table 15 : Summary of Pregnancy and Delivery Data in Group A and Group B	109
Table 16 : Summary of Serum Bilirubin and Onset of Jaundice in Neonates with and without Cardiac Affection	110
Table 17 : Summary and Statistical Analysis of Clinical and Laboratory Data Among Neonates of Group A and Group B	114

List of Figures

	Page
Figure 1 : Bilirubin formation and excretion	7
Figure 2 : Geographic distribution of reported kernicterus cases	16
Figure 3 : Distribution of peak TSB in term and near-term newborns with idiopathic jaundice	16
Figure 4 : Nomogram for hour-specific bilirubin values	22
Figure 5 : Indications for phototherapy and exchange transfusion in infants in 1996 in 108 NICUs	36
Figure 6 : AAP algorithm for the management of jaundice in the newborn nursery	39
Figure 7 : Guidelines for management of neonatal jaundice currently in use in most pediatric departments in Norway	41
Figure 8 : Diagram of subcostal long-axis views	54
Figure 9 : Diagram of subcostal short-axis (sagittal) views	55
Figure 10 : Diagram of abdominal views	56
Figure 11 : Diagram of two-dimensional echo views	57
Figure 12 : Diagram of apical long-axis views	58
Figure 13 : Diagram of important two-dimensional echo views	59
Figure 14 : Diagram of a family of parasternal short-axis views	60
Figure 15 : Diagram of suprasternal notch two-dimensional echo Views	62
Figure 16 : Diagram of subclavicular views	63
Figure 17 : Diagram of a cross-sectional view of the left side of the heart along the long axis and M-mode recordings	66
Figure 18 : Degradation of heme into bilirubin	80

List of Figures continue.....

Figure 19	: Distribution of unconjugated hyperbilirubinemia cases among NICU admitted neonates during 3 consecutive months	88
Figure 20	: Sex distribution among studied cases	89
Figure 21	: The different groups of unconjugated hyperbilirubinemia	93
Figure 22	: Percentage of patients with suspected hemolysis	96
Figure 23	: Exchange transfusion among studied cases	98
Figure 24	: FS% different groups of unconjugated hyperbilirubinemia (1,2,3)	100
Figure 25	: Cardiac affection distribution for all cases	101
Figure 26	: Parasternal echocardiographic views of a patient with affected cardiac contractility	103
Figure 27	: M-mode echo views in patients of group A at the level of ventricles	104
Figure 28	: M-mode echo view at level of aorta, left atrium and ventricles of a patient with affected cardiac contractility	105
Figure 29	: Gender distribution in group A (with cardiologic affection) and in group B (without cardiologic affection)	106
Figure 30	: Distribution of the unconjugated bilirubin level (mg/dl) in the cardiac neonates (group A), non – cardiac neonates (group B) and in all studied neonates (whole cases)	111
Figure 31	: Hemolysis distribution among group A (with cardiac affection) and group B (with no cardiac affection)	113
Figure 32	: Percentage of patients needing exchange transfusion in group A (with cardiac affection) and in group B (without cardiac affection)	115
Figure 33	: Follow-up echo of patients with affected cardiac contractility as proven by decreased FS%	117
Figure 34	: Follow up echo of other patients showing improved cardiac functions reaching normal values	118

List of Abbreviations

AAP	=	American Academy of Pediatrics
ABE	=	Acute bilirubin encephalopathy
AO	=	Aortic outflow
Azg. v	=	Azygos vein
B/A	=	Bilirubin / Albumin ratio
BMG	=	Bilirubin monoglucuronide
BDG	=	Bilirubin dinoglucuronide
CW	=	Continuous wave
DAT-test	=	Direct anti globulin test
EF	=	Ejection fraction
EGF	=	Epidermal growth factor
ET	=	Ejection time
FH	=	Family history
FS	=	Fractional shortening
G6PD	=	Glucose 6-phosphate dehydrogenase
LA	=	Left atrium
LV	=	Left ventricle
LVEDD	=	Left ventricular enddiastolic diameter
LVESD	=	Left ventricular endsystolic diameter
IVIG	=	Intravenous immune globulin
LVPW	=	Left ventricular posterior wall
IVS	=	Interventricular septum
MV	=	Mitral valve
NICU	=	Neonatal intensive care unit
OATP	=	Organic anion transporter
PA	=	Pulmonary artery
PAP	=	Pulmonary artery pressure
PPHN	=	Persistent pulmonary hypertension
PW	=	Posterior wall
RA	=	Right atrium
ROS	=	Reactive oxygen species
RPV	=	Right pulmonary vein
RV	=	Right ventricle
RVOT	=	Right ventricular outflow tract
SV	=	Stroke volume
SVC	=	Superior vena cava

List of Abbreviations continue

TcB	=	Transcutaneous bilirubin
TSB	=	Total serum bilirubin
TV	=	Tricuspid valve
UCB	=	Unconjugated bilirubin
UDPGT	=	Uridine diphosphate-glucuronyl transferase

Abstract

Introduction: Jaundice affects nearly 60% of term and 80% of preterm neonates during the first week of life. Unconjugated hyperbilirubinemia may result in severe medical conditions when left untreated. The most serious of them is encephalopathy. Cardiac affection was also reported in many studies.

The aim of this work: was to study prospectively the effects of unconjugated hyperbilirubinemia on the cardiovascular status and myocardial function in jaundiced neonates admitted to Cairo University NICU over a period of 3 consecutive months (May to July 2009).

Patients and methods: The study included 135 neonates. We studied the impact of different clinical parameters (e.g. mode of delivery, gestational age, admission weight, etc.) and laboratory parameters (e.g. level of total and unconjugated bilirubin on admission and after 48 hours, hemoglobin, etc.) on the cardiac functions measured by echocardiography.

Results: The studied patients represented 46.1% of all admissions in these 3 months. Males were more prevalent than females (54.8% versus 45.2%). The gestational ages ranged from 35 weeks to 40 weeks, and their admission's weights varied from 1.5 to 4.5 kg. The jaundice was noticed from day 1 to as late as day 7, while the admission ages ranged from 1 day to 27 days. On admission, total serum bilirubin ranged from 6.7 to 45.8 mg/dl and unconjugated bilirubin ranges were from 6.4 to 42.9 mg/dl. Other parameters also were measured e.g. hemoglobin, albumin, B/A ratio, potassium etc. Nineteen percent of the studied cases had fractional shortening below 30% as documented by echocardiography, indicating affection of left ventricular systolic function. Cases with cardiac affection had significantly higher bilirubin levels and B/A ratio on admission than cases without cardiac affection. They also showed increased left ventricular enddiastolic, left

ventricular endsystolic, aortic outlet and left atrial measurements. On follow up after 1 month for reevaluation of their echocardiographic findings, only 10 cases came. Three out of the ten cases had still an affection of cardiac contractility and were referred to cardiology clinic.

Conclusion: Neonatal unconjugated hyperbilirubinemia is still a main cause of admission to the NICU. The public and professional awareness of the problems associated with neonatal jaundice should be highlighted and affection of cardiac contractility should also be considered. Patients with severe hyperbilirubinemia (> 25 mg/dl) are more susceptible to cardiac affection. Early detection and follow up of cases with high unconjugated hyperbilirubinemia are recommended.

KEY WORD: NEONTES-UNCONJUGATED-ECHOCARDIOGRAPHY-SVC

Introduction

Neonatal hyperbilirubinemia is extremely common, because almost every newborn develops an unconjugated serum bilirubin level more than 30 μ mol/l (1.8 mg/dl) during the first week of life. Jaundice in neonates is common affecting nearly 60% of term and 80% of preterm neonates during the first week of life (*Agarwal and Deorari, 2002*). Almost all newborn infants develop a total serum bilirubin (TSB) level greater than 1 mg/dl (17 micromol/l), which is the upper limit of healthy adults. As the TSB increases, it produces a yellowish discoloration of the skin and/or sclerae caused by bilirubin deposition, and this is called jaundice (*Dennery et al., 2001*).

Incidence figures are difficult to compare because authors of different studies do not use the same definitions for significant neonatal jaundice. Also, incidence, extent and duration of elevation of total serum bilirubin vary among populations of different racial and geographic distributions (*Madan et al., 2005*).

Hyperbilirubinemia may be conjugated or unconjugated. Conjugated hyperbilirubinemia is due to hepatic and post hepatic causes. The unconjugated hyperbilirubinemia may be physiological or non physiological. In most infants, unconjugated hyperbilirubinemia reflects a normal transitional phenomenon (physiologic jaundice). This jaundice is caused by a combination of increased bilirubin production secondary to accelerated destruction of erythrocytes, decreased excretory capacity secondary to low levels of ligandin in hepatocytes, and low activity of the bilirubin-conjugating enzyme UDPGT (*Hansen, 2011*).

Pathologic neonatal jaundice with unconjugated hyperbilirubinemia occurs when additional factors accompany the basic mechanisms described above. These factors may lead to hemolysis (hemolytic jaundice) or nonhemolytic jaundice. Hemolytic factors include intrinsic causes e.g. G6PD deficiency and spherocytosis. Extrinsic factors include: alloimmunity due to ABO and RH incompatibility (hemolytic disease of the newborn). Nonhemolytic causes include cephalhematoma and polycythemia (*Piazza and Stoll, 2007*).

Hyperbilirubinemia may require therapy, which is mainly in the form of phototherapy or exchange transfusion. The values for this in infants of 35 weeks gestation follow specific curves (*AAP, 2004*) and in preterms less than 35 weeks of gestation the choice of therapy depends on the weight (*Cloherly et al., 2008*).

Unconjugated hyperbilirubinemia may result in severe medical conditions when left untreated. The most serious of them is encephalopathy. Cardiac affection due to unconjugated hyperbilirubinemia was reported in many studies. In 1990, a study reported a significant, but previously unrecognized cardiac hypertrophy with disproportionate septal hypertrophy in patients with erythroblastosis fetalis (*Carter et al., 1990*). Left ventricle (LV) systolic dysfunction was detected in full-term neonatal with unconjugated hyperbilirubinemia caused by decreased conjugating activity and hemolytic disease of the newborn. This finding was documented by echocardiography (*Prakhov and Girshovich, 2004*).

Aim Of Work

The main objectives of this work are:

- To prospectively study neonates with unconjugated hyperbilirubinemia admitted to Cairo University Neonatal Intensive Care Unit (NICU) for therapy over a period of 3 consecutive months.
- To assess the cardiovascular status of the patient and myocardial function by echocardiography.
- Obtained data analysis may shed some light on the effect of unconjugated hyperbilirubinemia on the cardiovascular affection in neonates.

Neonatal Hyperbilirubinemia

Definition

Neonatal hyperbilirubinemia is defined as a total serum bilirubin level above 5 mg per dL (86 μ mol per L). Deposition of unconjugated bilirubin pigment in the skin and mucus membranes results in neonatal jaundice, which is manifested as some degree of yellowness of the skin or sclera, occurring when the total serum bilirubin level exceeds 5-6 mg/dl. Neonatal jaundice is a very common condition worldwide occurring in up to 60% of term and 80% of preterm newborns in the first week of life, where few have significant underlying disease (*Slusher et al., 2004*). In most cases, the total serum bilirubin concentrations (TSB) do not exceed the normal range, the upper limit for which may be defined as the 95th percentile for hour of life (*Haque and Rahman, 2000*). However, hyperbilirubinemia in the newborn period can be associated with severe illnesses such as hemolytic disease, metabolic and endocrine disorders, anatomic abnormalities of the liver, and infections. Depending on the patient group under consideration, TSB values peak on the 3rd to 4th day of life. The 95th percentile at this age corresponds to TSB concentrations of 15.0 mg/dl to 17.0 mg/dl (*Maisels, 2001*). Even though extreme hyperbilirubinemia is rare in developed countries it is still quite high in developing countries often resulting in kernicterus with its attendant medical, economic and social burden on the patient, family and society at large (*Wang et al., 2005; Ho, 2002*).